- Home
- SCNI vs XRTX Comparison
SCNI vs XRTX Comparison
Compare SCNI & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- XRTX
- Stock Information
- Founded
- SCNI 2003
- XRTX 2011
- Country
- SCNI Israel
- XRTX Canada
- Employees
- SCNI N/A
- XRTX N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- XRTX Pharmaceuticals and Biotechnology
- Sector
- SCNI Health Care
- XRTX Health Care
- Exchange
- SCNI Nasdaq
- XRTX Nasdaq
- Market Cap
- SCNI 3.5M
- XRTX 4.1M
- IPO Year
- SCNI N/A
- XRTX N/A
- Fundamental
- Price
- SCNI $3.39
- XRTX $1.12
- Analyst Decision
- SCNI
- XRTX Strong Buy
- Analyst Count
- SCNI 0
- XRTX 1
- Target Price
- SCNI N/A
- XRTX $14.00
- AVG Volume (30 Days)
- SCNI 13.0K
- XRTX 15.6K
- Earning Date
- SCNI 11-22-2024
- XRTX 11-15-2024
- Dividend Yield
- SCNI N/A
- XRTX N/A
- EPS Growth
- SCNI N/A
- XRTX N/A
- EPS
- SCNI 8.20
- XRTX N/A
- Revenue
- SCNI $452,000.00
- XRTX N/A
- Revenue This Year
- SCNI N/A
- XRTX N/A
- Revenue Next Year
- SCNI N/A
- XRTX N/A
- P/E Ratio
- SCNI $0.42
- XRTX N/A
- Revenue Growth
- SCNI N/A
- XRTX N/A
- 52 Week Low
- SCNI $2.23
- XRTX $1.09
- 52 Week High
- SCNI $8.92
- XRTX $7.00
- Technical
- Relative Strength Index (RSI)
- SCNI 51.16
- XRTX 38.93
- Support Level
- SCNI $3.20
- XRTX $1.14
- Resistance Level
- SCNI $3.55
- XRTX $1.25
- Average True Range (ATR)
- SCNI 0.19
- XRTX 0.10
- MACD
- SCNI 0.02
- XRTX 0.01
- Stochastic Oscillator
- SCNI 47.50
- XRTX 0.00
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.